Penny stock under ₹2 hits upper circuit for 20th straight session. Do you own?
The penny stock has been hitting upper circuit for the past twenty trading sessions, and has been on an uptrend in thirty consecutive sessions. It has jumped over 81% in the past thirty sessions.
Avance Technologies recently announced the date for its board meeting, wherein the members of its board will consider Q1 results.
The meeting of the Board of Directors of Avance Technologies is scheduled to be held on Thursday, 14 August, 2025, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2025, Avance Technologies said in a regulatory filing on August 8.
The company's board of directors will also consider the proposal for raising of funds by way of preferential issue, rights issue, qualified institutional placement (QIP), or any other permissible mode, subject to such regulatory or statutory approvals as may be required.
'Further, pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in the securities of the Company, which has been closed from 1st July, 2025, will reopen 48 hours after the declaration of the financial results,' said the company.
Avance Technologies share price has surged 51% over the past month and delivered multibagger gains of 165% in three months. The small-cap stock has rallied 114% in the last six months and is up 77% on a year-to-date (YTD) basis.
Over a two-year period, the penny stock has generated returns of 500%, while delivering a staggering 3,800% gain in the past five years.
At 11:45 AM, Avance Technologies share price was still locked at 2% upper circuit of ₹ 1.56 apiece on the BSE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
an hour ago
- Hans India
Cohance Lifesciences Announces ₹230 mn Investment and Progress on cGMP Oligonucleotide Facility at Hyderabad, India
Cohance Lifesciences Limited ('Cohance' or 'the Company'), a partner of choice for global innovator pharma companies, announced INR 230 million investment and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India. This strategic investment strengthens Cohance's integrated oligonucleotide platform and enhances its position as a preferred partner for emerging modalities. Cohance brings deep expertise in modified nucleosides and locked nucleic acids (LNA), with a proven track record in complex nucleoside and nucleic acid synthesis at the R&D stage. The new facility will enable the Company to take these high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics. Integrated with pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. This scale, combined with advanced environmental controls including ISO Class 8 clean rooms and RH-controlled areas, is designed to meet the stringent requirements of complex oligonucleotide building block production. Customer engagements are already underway, with audits planned in the coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence in CY26. Vivek Sharma, Executive Chairman, Cohance Lifesciences, said: 'Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics.' This investment follows the Company's recently announced USD 10 million expansion of cGMP bioconjugation capabilities at NJ Bio in the United States. Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply.
Mint
an hour ago
- Mint
Sebi gets interim relief as HC halts special court order to probe a 1995 IPO
Can a special court order the Securities and Exchange Board of India (Sebi) to initiate investigation of alleged malfeasance brought to its notice by an investor? The Bombay high court is currently seized of such a case, and the final outcome could reinforce the line between judicial overreach and regulatory autonomy. The Bombay high court has in the interim stayed a special court's order that directed Sebi to investigate alleged irregularities in Radhe Developers' December 1995 listing on the BSE, after an investor sought a court-ordered probe through the criminal procedure route. The interim stay halts the special court's 23 January order, which required Sebi to investigate and file an action taken report, till the High Court hears the case again. The matter, listed in mid-June, is expected to be taken up again later this month. A single-judge bench of Justice R.N. Laddha issued notice to the complainant on Sebi's revision plea and recorded the regulator's core position: special courts under the Sebi Act are meant to try offences on complaints instituted by Sebi, and do not have the jurisdiction to compel the regulator to open investigations or supervise how it exercises its administrative powers. In its April order, the high court highlighted Sebi's challenge to the special court's authority and stayed the 'execution, operation and implementation" of the impugned order. The underlying proceedings stem from a complaint by investor and legal reporter Sapan Shrivastava, who alleged that the Gujarat-based realty developer Radhe Developers was listed on the BSE in December 1995 without complying with Sebi's listing norms and sought directions under Section 156(3) of the Criminal Procedure Code (CrPC), which empowers a magistrate to direct initiation of an investigation. Also Read: Sebi chief urges redefining role of independent directors as stewards of accountability While acknowledging that Section 26 of the Sebi Act allows cognisance of offences only on a complaint by the regulator, the special court nevertheless held it could direct Sebi to investigate in investors' interest, and ordered the regulator to inquire and report back. Arguing before the High Court, Sebi said that Section 156(3) CrPC is confined to directing police to investigate cognisable offences and cannot be applied to statutory regulators operating under their own enabling law. The regulator also stressed that special courts are designed for expeditious trial of offences arising under the Sebi Act upon a Sebi-filed complaint, not to mandate investigations or control Sebi's discretion at the pre-complaint stage. Shares of Radhe Developers closed 3.5% lower at ₹2.74 apiece on the BSE on Tuesday. Why this matters The case could reset the line between judicial oversight and regulatory autonomy in securities law enforcement, especially for investors attempting to revive scrutiny of legacy listings through criminal court applications. 'The role of a special court is to adjudicate offences brought before it, not to identify or investigate them in the first instance," Sachit Mathur, managing partner at Emerald Law Offices, said. Allowing special courts to direct Sebi to investigate would be an overreach and ultra vires, he said, warning it could disrupt Sebi's autonomy and the statutory design that vests investigation squarely with the regulator. Mathur added that magistrates' directions under the criminal procedure code extend only to police and do not bind Sebi. Investors can escalate grievances on SCORES, which is Sebi's online complaint redressal platform, approach Sebi's grievance cell, and, if needed, file a writ under Article 226 for a time-bound mandamus to consider the representation without dictating the outcome. Under Article 226 of the Indian Constitution, high courts can issue writs or directives for the enforcement of fundamental and other legal rights. Mandamus is one of the five writs, which is issued to force a public authority to perform a public duty. Aditya Bhansali, founding partner at Mindspright Legal, said the Sebi Act does not empower special courts to order Sebi to initiate an investigation on an investor's application, and Section 156(3) cannot compel statutory regulators to exercise investigative powers. 'The most effective lawful route for investors seeking action is to file a writ petition before the high court," he said, noting that while the Securities Appellate Tribunal (SAT) is an appellate forum, it is available only when there is an order by Sebi or an exchange, often absent where investors allege inaction. The Bombay high court's interim stay aligns with its recent caution against trial courts mechanically directing criminal or investigative measures in securities market cases without clear legal footing. Also Read: Sebi mulls framework to boost resident Indians participation in FPIs Earlier this year, it stayed an Anti-Corruption Bureau court's order directing registration of an FIR against former Sebi chair Madhabi Puri Buch and others, finding the order mechanical and non-specific. Rohit Jain, managing partner at Singhania & Co, said that directing an investigation would usurp a function reserved for the regulator and act before the court's jurisdiction properly begins. Implications for investors For investors, the case could reshape how Sebi's online grievance redressal platform SCORES and other remedies are used. As Bombay High Court counsel Yash Joglekar noted, Section 156(3) authorises directions to the officer in charge of a police station, not to Sebi. Legacy matters face added hurdles: laches from decades-long delays, incomplete listing records, and missing witnesses—while Section 26 of the Sebi Act bars criminal proceedings unless initiated by Sebi itself. The doctrine of laches is a legal principle under which legal claims can be barred due passage of an unreasonably long time. If the high court affirms that special courts cannot compel Sebi to investigate, the practical path shifts to administrative and constitutional routes, he said. 'Investors will have to rely on escalation through SCORES and the grievance cell, use RTI to seek reasons for inaction, approach SAT where there is an appealable order, and file writ petitions for time-bound consideration—without asking courts to micromanage outcomes." Tushar Kumar, advocate at the Supreme Court, cautioned that vintage listings pose severe practical barriers. 'Listings from the mid-1990s raise formidable obstacles—from limitation and laches to the retrieval of contemporaneous evidence, records and witnesses," he said. A ruling upholding Sebi's stance would entrench regulatory autonomy and curb ad hoc, court-driven probes, while pushing investors towards regulatory and constitutional remedies, he added. Also Read: Sebi rejects Anil Ambani's settlement plea over Yes Bank investments 'Such a pronouncement would reinforce the line between judicial oversight and regulatory independence and may trigger debate on narrowly tailored statutory channels for independent scrutiny in exceptional cases—preserving market integrity without undermining Sebi's functional autonomy."
Economic Times
7 hours ago
- Economic Times
Tata Power bets on renewable energy to drive future growth
ET Intelligence Group: Tata Power Company (TPCL) is ramping up investments in renewables, which have emerged as a key growth driver for profit and revenue. The segment's share of operating profit rose to 26.3% in FY25 from 19.2% in FY23. In the first quarter of FY26, this segment was the largest contributor to the company's operating profit before depreciation and amortisationm, or Ebitda. Renewables clocked an Ebitda of ₹1,567 crore, while TPCL's total Ebitda was ₹3,930 crore. Other divisions, including transmission and distribution (T&D), delivered an Ebitda of ₹ 1,345 crore, while that from thermal generation, coal, and hydro segment was ₹974 crore. The company plans to add 1.7 gigawatts (GW) of renewable energy capacity by the end of the current financial year, which will take its total installed renewables capacity to approximately 6.6 GW. The total clean energy capacity- including renewable, hydro, hybrid and Waste Heat Recovery Systems-was nearly 7 GW as of June. Adani Green Energy, in comparison, had a total renewable energy capacity of 14.2 GW at the end of FY25, comprising 10.1 GW of solar, 2 GW of wind, and 2.1 GW of hybrid power. Praveer Sinha, MD and CEO, TPCL, stated during an earnings call that the company's balance sheet was sturdy in spite of a sustained capital expenditure. "We spent in the June quarter ₹3,700 crore against our full year plan of ₹25,000 crore and we are on track to implement all those projects." The company is currently executing nearly 5.5 GW of renewable energy capacity. It has 2.8 GW of pumped hydro projects in progress, with 1 GW already under construction and the remaining 1.8 GW scheduled to begin within the next nine addition, work is underway on a 600-megawatt hydro project in Bhutan with plans to scale the total capacity to nearly 5 GW over the next few years. "These projects will give us either similar or better returns than what we will do in any other project," Sinha company's net debt has risen by nearly ₹2,900 crore to ₹47,578 crore in the first quarter of the current financial year due to higher capex and working capital Financial Institutional Securities expects the company's net profit to grow by 13% annually between FY25 and FY28. The broking firm has retained a 'buy' call on the stock with a target price of ₹436. The stock was last traded at ₹384.5 on Tuesday on the BSE.
